Clinical trials: ICP
Diabetes Mellitus, Insulin-Dependent
Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study
Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone.
- Conditions
- Diabetes Mellitus, Insulin-Dependent, Type 1
- Trial name
- NCT01973920
- Testing
- Oshadi Icp
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Oshadi Drug Administration
Inflammatory Bowel Disease(IBD)
Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers
This is a randomized, double-blind, placebo-controlled, ascending dose study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part (Part B).
- Trial name
- NCT07911982
- Testing
- ICP-B161 (SC or IV)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Intrahepatic Cholestasis of Pregnancy
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
Part 1 is an open-label randomized study of volixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability of two doses of volixibat.
- Trial name
- OHANA (NCT04718961)
- Testing
- Volixibat
- Where
- 20 sites in United States, New Zealand and 1 more
- Volunteers
- 4 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Intrahepatic Cholestasis of Pregnancy
MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)
This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in pregnant women with intrahepatic cholestasis of pregnancy (ICP).
- Trial name
- OASIS (NCT07823127)
- Testing
- Maralixibat
- Volunteers
- 15 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Cerebral Autoregulation Impairment, Postoperative Cognitive Dysfunction
BrainProtect-guided, Real-time Cerebral Autoregulation Monitoring and Protection of Brain During Cardiac Surgery With Cardiopulmonary Bypass Requiring Heart-lung Machine
The purpose of this clinical investigation is to evaluate the clinical performance, safety, and clinical benefit of the BrainProtect System in reducing early postoperative neurological complications in adult participants…
- Conditions
- Cerebral Autoregulation Impairment, Postoperative Cognitive Dysfunction, Postoperative Delirium
- Trial name
- BrainProtect (NCT07872982)
- Testing
- BrainProtect System, Standard perioperative management
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 304 people
- Sponsor
- Scienceforbrain, UAB
Intracranial Hypertension
Comparison of the Non-invasive ICP HeadSense Monitor vs Lumbar CSF Pressure Measurement
In current practice patients with a suspected increase of intracranial pressure (ICP) will undergo a lumbar puncture with measurement of cerebral spinal fluid (CSF) pressure (as a marker for ICP).
- Trial name
- NCT02773901
- Testing
- HS-1000
- Where
- 3 sites in Denmark, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- HeadSense Medical
Advanced Solid Tumor
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
- Trial name
- NCT07617493
- Testing
- ICP-B208
- Where
- China
- Volunteers
- 539 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.